Cite
HARVARD Citation
O'Cearbhaill, R. et al. (n.d.). 945PA phase I/II study of chemo-immunotherapy with durvalumab (durva) and pegylated liposomal doxorubicin (PLD) in platinum-resistant recurrent ovarian cancer (PROC). Annals of oncology. p. . [Online].